Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

At 48 weeks, 62% in an experimental diabetes drug trial had non-diabetic blood sugar levels

Summary by stocktitan.net
At 24 mg, 90% hit the HbA1c target with a 2.65% average reduction; Genentech plans Phase III glycemic studies in the first half of 2027.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

stocktitan.netstocktitan.net

At 48 weeks, 62% in an experimental diabetes drug trial had non-diabetic blood sugar levels

At 24 mg, 90% hit the HbA1c target with a 2.65% average reduction; Genentech plans Phase III glycemic studies in the first half of 2027.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news on Tuesday, September 22, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

Basel icon

Basel

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal